R6 Ballot (1st Draft)

This page is part of the FHIR Specification v6.0.0-ballot1: Release 6 Ballot (1st Draft) (see Ballot Notes). The current version is 5.0.0. For a full list of available versions, see the Directory of published versions

Example ClinicalUseDefinition/example-interaction (Narrative)

Biomedical Research and Regulation Work GroupMaturity Level: N/AStandards Status: InformativeCompartments: No defined compartments

This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile ClinicalUseDefinition.

Generated Narrative: ClinicalUseDefinition

Resource ClinicalUseDefinition "example-interaction"

StructureDefinition Work Group: brr

type: interaction

subject: MedicinalProductDefinition/example

interaction

interactant

item: alphaconazole (interactant#alphaconazole)

interactant

item: betaconazole (interactant#betaconazole)

type: Inhibitor (interactionsType#Inhibitor)

Effects

-Concept
*Increased plasma concentration ()

management: Careful monitoring of dose ()

 

 

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.